Kidney Cancer—New Insights into Diagnosis and Treatment

A special issue of Uro (ISSN 2673-4397).

Deadline for manuscript submissions: closed (31 July 2022) | Viewed by 500

Special Issue Editor

E-Mail Website
Guest Editor
University Center of Excellence in Urology, Department of Minimally Invasive and Robotic Urology, Wroclaw Medical University, 50-556 Wroclaw, Poland
Interests: uro-oncology; lymph node metastasis-growth and immune evasion; minimally invasive surgery; radio-guided surgery; prostate cancer; bladder cancer
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In 2020, 431,288 new cases and 179,368 deaths from kidney cancer were recorded worldwide, which places this disease at the forefront of cancers. Even if in most cases the initial treatment is curative, a certain number of patients experience a poor course of disease with local or distant recurrence and require further treatment, which significantly worsens their quality of life.

Over the past two decades, great efforts have been made to improve diagnosis and treatment outcomes. Molecular biomarkers have been investigated and introduced into clinical practice, and new pathological and clinical classifications have been proposed to account for tumor behavior and risk of disease recurrence. At the same time, new surgical and pharmacological approaches have been developed to improve treatment outcomes.

Nevertheless, many aspects remain a matter of debate regarding accurate diagnosis, targeted therapy, and multidisciplinary management.

This Special Issue of Cancers will cover all aspects of kidney cancer, including original research into advanced imaging, molecular characterization, current and experimental treatment options, and quality of life. Expert opinions, systematic reviews, and meta-analyses are also welcome.

Dr. Bartosz Małkiewicz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Uro is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • kidney cancer
  • radical nephrectomy
  • cytoreductive nephrectomy
  • nephron-sparing surgery
  • minimally invasive and robotic surgery
  • prognostic biomarkers
  • localized/Metastatic disease
  • cancer biomarkers
  • immunotherapy
  • genomic biomarkers

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop